Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

被引：0

作者：

Weisel, K. ^{[1
]}

Palumbo, A. ^{[2
]}

Chanan-Khan, A. ^{[3
]}

Nooka, A. K. ^{[4
]}

Spicka, I. ^{[5
]}

Masszi, T. ^{[6
]}

Beksac, M. ^{[7
]}

Hungria, V. ^{[8
]}

Munder, M. ^{[9
]}

Mateos, M-V. ^{[10
]}

Mark, T. M. ^{[11
]}

Spencer, A. ^{[12
]}

Qi, M. ^{[13
]}

Schecter, J. ^{[14
]}

Amin, H. ^{[14
]}

Qin, X. ^{[15
]}

Deraedt, W. ^{[16
]}

Ahmadi, T. ^{[13
]}

Sonneveld, P. ^{[17
]}

机构：

[1] Eberhard Karls Univ Tubingen, Univ Klinikum Tuebingen, Dept Hematol Oncol Immunol Rheumatol & Pulmonol, Abt Innere Med 2, Tubingen, Germany

[2] Univ Turin, Dept Hematol, Turin, Italy

[3] Mayo Clin Florida, Div Hematol & Med Oncol, Jacksonville, FL USA

[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[5] Charles Univ Prague, Med Dept 1, Dept Clin Haematol, Prague, Czech Republic

[6] Semmelweis Univ, St Laszlo Hosp, Dept Haematol & Stem Cell Transplantat, Budapest, Hungary

[7] Ankara Univ, Dept Hematol, Ankara, Turkey

[8] Irmandade Santa Casa De Misericordia Sao Paulo, Sao Paulo, Brazil

[9] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany

[10] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[11] Weill Cornell Med Coll, New York, NY USA

[12] Monash Univ, Malignant Haematol & Stem Cell Transplantat Serv, Alfred Hlth, Melbourne, Vic, Australia

[13] Janssen Res & Dev LLC, Spring House, PA USA

[14] Janssen Res & Dev LLC, Raritan, NJ USA

[15] Janssen Res & Dev LLC, Horsham, PA USA

[16] Janssen Res & Dev, Beerse, Belgium

[17] Erasmus MC, Dept Hematol, Rotterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw375.1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

906O

引用

页数：1

共 50 条

[21] COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) AND DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) VERSUS STANDARD OF CARE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Pelligra, C.
Guo, S.
Parikh, K.
Zhang, S.
Krotneva, M.
Onyekwere, U.
Clancy, Z.
VALUE IN HEALTH, 2018, 21 : S254 - S254
[22] DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
Mateos, Maria-Victoria
Robak, Pawel
Hus, Marek
Fu, Chengcheng
Zherebtsova, Vera
Ward, Christopher
Ho, P. Joy
de Almeida, Ana Carolina
Hajek, Roman
Kim, Kihyun
Dimopoulos, Meletios Athanasios
Cerchione, Claudio
Pirooz, Nicholas
McKeown, Astrid
Kazeem, Gbenga
Baig, Hena
Eccersley, Lydia
Roy-Ghanta, Sumita
Opalinska, Joanna
Hungria, Vania
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
Mateos, Maria-Victoria
Richardson, Paul
Weisel, Katja
Moreau, Philippe
San-Miguel, Jesus
Goldschmidt, Hartmut
Orlowski, Robert
Sonneveld, Pieter
Reece, Donna E.
Suzuki, Kenshi
Bahlis, Nizar
Yoon, Sung-Soo
Spencer, Andrew
Nooka, Ajay
Hungria, Vania
Plesner, Torben
Ben Yehuda, Dina
Pei, Huiling
Mayo, Wendy Garvin
Gai, Xue
Carey, Jodi
Carson, Robin
Dimopoulos, Meletios A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S179 - S180
[24] Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM)
Hungria, Vania
Robak, Pawel
Hus, Marek
Fu, Chengcheng
Zherebtsova, Vera
Ward, Christopher
De Almeida, Ana Carolina
Ho, P. Joy
Hajek, Roman
Cerchione, Claudio
Pirooz, Nicholas
McKeown, Astrid
Baig, Hena
Eccersley, Lydia
Pompilus, Farrah
McNamara, Simon
Lin, Chee Paul
Roy-Ghanta, Sumita
Opalinska, Joanna
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
He, Jianming
Berringer, Heather
Heeg, Bart
Kampfenkel, Tobias
Dwarakanathan, Harikumaran R.
Johnston, Stephen
Mendes, Joao
Lam, Annette
Bathija, Sacheeta
Mackay, Eric
BLOOD, 2021, 138
[26] Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory of LEPUS
Fu, Weijun
Li, Wei
Hu, Jianda
An, Gang
Wang, Yafei
Fu, Chengcheng
Chen, Lijuan
Jin, Jie
Cen, Xinan
Ge, Zheng
Cai, Zhen
Niu, Ting
Qi, Ming
Gai, Xue
Li, Qian
Liu, Weiping
Liu, Wenyu
Yang, Xue
Chen, Xi
Lu, Jin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (01): : E51 - E58
[27] Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
Richardson, Paul G.
Rocafiguera, Albert Oriol
Beksac, Meral
Liberati, Anna Marina
Galli, Monica
Schjesvold, Fredrik
Lindsay, Jindriska
Weisel, Katja
White, Darell
Facon, Thierry
San-Miguel, Jesus
Sunami, Kazutaka
O'Gorman, Peter
Sonneveld, Pieter
Yu, Xin
Doerr, Thomas
Bensmaine, Amine
Zaki, Mohamed H.
Anderson, Kenneth Carl
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[28] Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor
Weisel, Katja C.
Sonneveld, Pieter
Mateos, Maria-Victoria
Hungria, Vania T. M.
Spencer, Andrew
Estell, Jane
Barreto, Wolney G.
Corradini, Paolo
Min, Chang-Ki
Medvedova, Eva
Krevvata, Maria
Trivedi, Sonali
Qin, Xiang
Pei, Huiling
Ukropec, Jon
Kobos, Rachel
Qi, Ming
Nooka, Ajay K.
BLOOD, 2019, 134
[29] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Knop, Stefan
Lonial, Sagar
Richardson, Paul
Popat, Rakesh
Stadtmauer, Edward A.
Larsen, Jeremy T.
Oriol, Albert
Jagannath, Sundar
Cook, Gordon
Badros, Ashraf Z.
Rodriguez-Otero, Paula
Siegel, David
Nguyen, Tuong Vi
Di Micco, Antonia
Amin, Alpesh
Chen, Min
Kueenburg, Elisabeth
Van De Donk, Niels W. C. J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 171 - 171
[30] Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Weisel, Katja
Spencer, Andrew
Lentzsch, Suzanne
Avet-Loiseau, Herve
Mark, Tomer M.
Spicka, Ivan
Masszi, Tamas
Lauri, Birgitta
Levin, Mark-David
Bosi, Alberto
Hungria, Vania
Cavo, Michele
Lee, Je-Jung
Nooka, Ajay
Quach, Hang
Munder, Markus
Lee, Cindy
Barreto, Wolney
Corradini, Paolo
Min, Chang-Ki
Chanan-Khan, Asher A.
Horvath, Noemi
Capra, Marcelo
Beksac, Meral
Ovilla, Roberto
Jo, Jae-Cheol
Shin, Ho-Jin
Sonneveld, Pieter
Casneuf, Tineke
DeAngelis, Nikki
Amin, Himal
Ukropec, Jon
Kobos, Rachel
Mateos, Maria-Victoria
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)

← 1 2 3 4 5 →